ZHANG Shao-hua, ZHANG Jun-sheng. Pambrolizumab Is Expected to Change the Choice of First-Line Treatment for Advanced Triple-Negative Breast Cancer: Review the KEYNOTE-355 Study[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 76-78. DOI: 10.12019/j.issn.1671-5144.2021.02.003
|
Citation:
|
ZHANG Shao-hua, ZHANG Jun-sheng. Pambrolizumab Is Expected to Change the Choice of First-Line Treatment for Advanced Triple-Negative Breast Cancer: Review the KEYNOTE-355 Study[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 76-78. DOI: 10.12019/j.issn.1671-5144.2021.02.003
|
ZHANG Shao-hua, ZHANG Jun-sheng. Pambrolizumab Is Expected to Change the Choice of First-Line Treatment for Advanced Triple-Negative Breast Cancer: Review the KEYNOTE-355 Study[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 76-78. DOI: 10.12019/j.issn.1671-5144.2021.02.003
|
Citation:
|
ZHANG Shao-hua, ZHANG Jun-sheng. Pambrolizumab Is Expected to Change the Choice of First-Line Treatment for Advanced Triple-Negative Breast Cancer: Review the KEYNOTE-355 Study[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 76-78. DOI: 10.12019/j.issn.1671-5144.2021.02.003
|
DownLoad: